Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China And Taiwan Move Toward Clinical Data Mutual Acceptance, Regulatory Harmonization

This article was originally published in PharmAsia News

Executive Summary

China and Taiwan's top health regulators have signed an agreement to harmonize clinical and non-clinical studies toward mutual data acceptance. The deal could open doors for more Taiwanese drugs in the Chinese market, industry experts say

You may also be interested in...



Bayer Global Regulatory Affairs Head Joseph Scheeren On MRCT In China: An Interview With PharmAsia News

The possibility China may scale back the acceptance of Multi-Regional Clinical Trial (MRCT) data has become a hot topic between China FDA and industry. On the sidelines of a recent special Asia Pacific Economic Cooperation (APEC) meeting on regional clinical trials, Joseph Scheeren, head of global regulatory affairs for Bayer, shares his views.

Slow Take Off For Taiwan’s Fast-Track NDA Program

Taiwan’s new fast-track NDA process is expected to reduce review time from 360 days to 200, or even less for three categories of drugs.

More Efforts Needed To Make Taiwan A Springboard To China – BioBusiness Asia Conference

Cooperation is needed between pharma partners in addition to implementation of cross-strait agreements.

Related Content

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel